Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials

BACKGROUND AND AIMS: In the 4-week GAIN clinical trial, adalimumab was efficacious in inducing remission in patients with moderate-to-severe Crohn’s disease [CD] who had prior loss of response/intolerance to infliximab. The efficacy and safety of adalimumab in these patients are reported here for up...

Descripción completa

Detalles Bibliográficos
Autores principales: Panaccione, Remo, Sandborn, William J, D’Haens, Geert, Wolf, Douglas C, Berg, Sofie, Maa, Jen-fue, Petersson, Joel, Robinson, Anne M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065484/
https://www.ncbi.nlm.nih.gov/pubmed/29697818
http://dx.doi.org/10.1093/ecco-jcc/jjy050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065484/
https://www.ncbi.nlm.nih.gov/pubmed/29697818
http://dx.doi.org/10.1093/ecco-jcc/jjy050

Ejemplares similares